Wealth Manager - the site for professional investment managers

Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

The fund managers boosted by Shire bid

The fund managers boosted by Shire bid
 

Shares in Shire (SHP) have jumped to the top of the FTSE 100 after Japan's largest drugmaker Takeda Pharmaceutical (4502.T) said it was considering a bid for the company.

Shares in the pharmaceutical group jumped 17.3% to £35.98, providing a boost to backers of the stock, which is popular among value-focused fund managers.

Jamie Seaton is the highest conviction investor in the stock, having built up a 9.9% position in his £321 million GVQ UK Focus. That's just below the 10% limit imposed by Financial Conduct Authority regulations, meaning today's jump is likely to force him to sell some of the stake.

The stock is meanwhile a top 5 position for Paul Major, manager of the BB Healthcare (BBH) investment trust, accounting for 5% of the portfolio.

Shire has attracted backing from a number of value-focused investors, as its shares have drifted lower this year amid greater competition from generic drugs.

Alex Wright holds 3% of his Fidelity Special Values (FSV) investment trust in the shares, while his colleague James Griffin has a 3.4% stake in his £561 million Fidelity Moneybuilder Growth fund.

Thomas Wilson is also a backer, with 3.9% of his £61 million F&C UK Alpha fund in the stock, while colleague David Moss has a 3.9% holding in the £61 million F&C UK Equity Income fund.

Other fund manager investors include Scott McKenzie, with 4.6% of his £14 million Saracen UK Alpha fund held in the stock; Henry Flockhart, with a 3.9% position in his £235 million Standard Life Investments UK Equity High Alpha fund; and Luke Chappell, with 3.3% of his £307 million BlackRock UK Equity fund.

Ketan Patel, co-manager of the EdenTree Amity UK fund, said a Takeda takeover would be 'a watershed moment for Japanese pharma'.

'There hasn’t been a cross border transaction in the sector, excluding joint ventures and small generic mergers and acquisitions,' he said.

'Takeda’s cash laden balance sheet appears a good fit for Shire’s struggling balance sheet, following recent large-scale mergers and acquisitions. The attraction for Takeda is the highly lucrative rare disease market in the US, which comes with exceedingly high margins and is largely exempt from the usual pricing pressure that affects the wider pharmaceutical sector.' 

Patel holds Shire in his EdenTree UK Equity Growth fund, which he runs with Phil Harris.

Takeda said its approach was 'at a preliminary and exploratory stage and no approach has been made to the board of Shire'.

Jefferies analyst Peter Welford, who rates Shire a 'buy', said he could 'see the potential strategic rationale for the deal' but flagged concerns over Takeda's relative size.

'We see the possible strategic fit given the Japanese pharma's focus  therapeutic areas of oncology, gastrointestinal and neuroscience, with Shire bolstering the latter two franchises,' he said.

'We note Takeda's current market cap is around $42 billion, which compares to Shire's $47 billion. We presume Takeda would need a significant equity raise to acquire Shire, suggesting a "merger" is perhaps better terminology, which may raise hurdles to the successful completion of any future deal.'

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

Related Fund Managers

Thomas Wilson
Thomas Wilson
7/14 in Equity - UK Medium Companies (Performance over 3 years) Average Total Return: 26.56%
Philip Harris
Philip Harris
47/185 in Equity - UK (All Companies) (Performance over 1 year) Average Total Return: 9.91%
Susan Round
Susan Round
127/153 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 17.07%
Ketan Patel
Ketan Patel
87/185 in Equity - UK (All Companies) (Performance over 1 year) Average Total Return: 7.86%
Luke Chappell
Luke Chappell
54/153 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 29.39%
Scott McKenzie
Scott McKenzie
4/185 in Equity - UK (All Companies) (Performance over 1 year) Average Total Return: 16.97%
David Moss
David Moss
58/205 in Equity - UK (All Companies) (Performance over 3 months) Average Total Return: 3.96%
James Griffin
James Griffin
144/153 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 11.73%
Alex Wright
Alex Wright
39/153 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 31.98%
Jamie Seaton
Jamie Seaton
122/153 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 17.38%
Henry Flockhart
Henry Flockhart
Your Business: Cover Star Club

Profile: the continuing story of jonathanfry, minus Jonathan Fry

Profile: the continuing story of jonathanfry, minus Jonathan Fry

It had gone a bit quiet at Gale & Phillipson since its merger with multi-family office jonathanfry in 2015

Wealth Manager on Twitter